{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:57:33Z","timestamp":1774677453725,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2002,8,1]]},"DOI":"10.1038\/sj.bmt.1703615","type":"journal-article","created":{"date-parts":[[2002,9,3]],"date-time":"2002-09-03T18:27:34Z","timestamp":1031077654000},"page":"141-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo"],"prefix":"10.1038","volume":"30","author":[{"given":"Z","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Hellstr\u00f6m-Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Alsadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Edgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"H\u00e4gglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,8,22]]},"reference":[{"key":"BF1703615_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/sj.bmt.1702823","volume":"27","author":"Z Hassan","year":"2001","unstructured":"Hassan Z, Ljungman P, Ringd\u00e9n O et al. Pharmacokinetics of liposomal busulphan in man Bone Marrow Transplant 2001 27: 479 485","journal-title":"Bone Marrow Transplant"},{"key":"BF1703615_CR2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V82.3.1030.1030","volume":"82","author":"G Vassal","year":"1993","unstructured":"Vassal G, Fischer A, Challine D et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease Blood 1993 82: 1030 1034","journal-title":"Blood"},{"key":"BF1703615_CR3","first-page":"18","volume":"20","author":"LB Grochow","year":"1993","unstructured":"Grochow LB . Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 1993 20: 18 25","journal-title":"Semin Oncol"},{"key":"BF1703615_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00694339","volume":"25","author":"LB Grochow","year":"1989","unstructured":"Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25: 55 61","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703615_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/BF00689702","volume":"28","author":"M Hassan","year":"1991","unstructured":"Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Cancer Chemother Pharmacol 1991 28: 130 134","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703615_CR6","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","volume":"84","author":"M Hassan","year":"1994","unstructured":"Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability Blood 1994 84: 2144 2150","journal-title":"Blood"},{"key":"BF1703615_CR7","first-page":"31","volume":"16","author":"JT Slattery","year":"1995","unstructured":"Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31 42","journal-title":"Bone Marrow Transplant"},{"key":"BF1703615_CR8","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood.V79.9.2475.2475","volume":"79","author":"G Vassal","year":"1992","unstructured":"Vassal G, Deroussent A, Challine D et al. Is 600 mg\/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992 79: 2475 2479","journal-title":"Blood"},{"key":"BF1703615_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/stem.5530110111","volume":"11","author":"MV Marshall","year":"1993","unstructured":"Marshall MV, Marshall MH, Degen DR et al. In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units Stem Cells 1993 11: 62 69","journal-title":"Stem Cells"},{"key":"BF1703615_CR10","first-page":"7555","volume":"50","author":"DY Pacheco","year":"1990","unstructured":"Pacheco DY, Cook C, Hincks JR et al. Mechanisms of toxicity of hepsulfam in human tumor cell lines Cancer Res 1990 50: 7555 7558","journal-title":"Cancer Res"},{"key":"BF1703615_CR11","first-page":"5108","volume":"49","author":"DY Pacheco","year":"1989","unstructured":"Pacheco DY, Stratton NK, Gibson NW . Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line Cancer Res 1989 49: 5108 5110","journal-title":"Cancer Res"},{"key":"BF1703615_CR12","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/sj.leu.2402193","volume":"15","author":"Z Hassan","year":"2001","unstructured":"Hassan Z, Hassan M, Hellstrom-Lindberg E . The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro Leukemia 2001 15: 1240 1247","journal-title":"Leukemia"},{"key":"BF1703615_CR13","first-page":"913","volume":"21","author":"JD Down","year":"1993","unstructured":"Down JD, Ploemacher RE . Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs Exp Hematol 1993 21: 913 921","journal-title":"Exp Hematol"},{"key":"BF1703615_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/bjc.1994.359","volume":"70","author":"JD Down","year":"1994","unstructured":"Down JD, Boudewijn A, Dillingh JH et al. Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs Br J Cancer 1994 70: 611 616","journal-title":"Br J Cancer"},{"key":"BF1703615_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/08923978609031088","volume":"8","author":"M Reynolds","year":"1986","unstructured":"Reynolds M, McCann SR . Sequential studies of bone marrow haemopoietic progenitors (CFU-GEM, BFU-E, CFU-E, CFU-GM) following busulfan treatment in Balb\/c mice J Immunopharmacol 1986 8: 99 116","journal-title":"J Immunopharmacol"},{"key":"BF1703615_CR16","first-page":"7559","volume":"50","author":"JR Hincks","year":"1990","unstructured":"Hincks JR, Adlakha A, Cook CA et al. In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients Cancer Res 1990 50: 7559 7563","journal-title":"Cancer Res"},{"key":"BF1703615_CR17","first-page":"6090","volume":"43","author":"K Kubota","year":"1983","unstructured":"Kubota K, Preisler HD, Costanzo C et al. In vitro busulfan sensitivity of granulocyte\u2013macrophage and erythroid progenitor cells in patients with chronic myelogenous leukemia Cancer Res 1983 43: 6090 6093","journal-title":"Cancer Res"},{"key":"BF1703615_CR18","first-page":"618","volume":"11","author":"HD Preisler","year":"1983","unstructured":"Preisler HD, Kirshner J . In vitro drug sensitivity studies of CFUc in chronic myelocytic leukemia: I. Suicide indices and busulfan sensitivity determinations during the chronic phase Exp Hematol 1983 11: 618 625","journal-title":"Exp Hematol"},{"key":"BF1703615_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/00001813-199210000-00014","volume":"3","author":"DP Berger","year":"1992","unstructured":"Berger DP, Winterhalter BR, Dengler WA et al. Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow Anticancer Drugs 1992 3: 531 539","journal-title":"Anticancer Drugs"},{"key":"BF1703615_CR20","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.V80.9.2425.2425","volume":"80","author":"AM Yeager","year":"1992","unstructured":"Yeager AM, Wagner JE, Graham ML et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation Blood 1992 80: 2425 2428","journal-title":"Blood"},{"key":"BF1703615_CR21","first-page":"6203","volume":"50","author":"G Vassal","year":"1990","unstructured":"Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study Cancer Res 1990 50: 6203 6207","journal-title":"Cancer Res"},{"key":"BF1703615_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","volume":"64","author":"E Carreras","year":"2000","unstructured":"Carreras E . Veno-occlusive disease of the liver after hemopoietic cell transplantation Eur J Haematol 2000 64: 281 291","journal-title":"Eur J Haematol"},{"key":"BF1703615_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/hep.510310224","volume":"31","author":"X Wang","year":"2000","unstructured":"Wang X, Kanel GC, DeLeve LD . Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat Hepatology 2000 31: 428 434","journal-title":"Hepatology"},{"key":"BF1703615_CR24","doi-asserted-by":"crossref","first-page":"17205","DOI":"10.1016\/S0021-9258(19)77815-6","volume":"263","author":"A Meister","year":"1988","unstructured":"Meister A . Glutathione metabolism and its selective modification J Biol Chem 1988 263: 17205 17208","journal-title":"J Biol Chem"},{"key":"BF1703615_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2165\/00002018-200022020-00005","volume":"22","author":"PA Chyka","year":"2000","unstructured":"Chyka PA, Butler AY, Holliman BJ et al. Utility of acetylcysteine in treating poisonings and adverse drug reactions Drug Saf 2000 22: 123 148","journal-title":"Drug Saf"},{"key":"BF1703615_CR26","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/sj.bmt.1702387","volume":"25","author":"O Ringden","year":"2000","unstructured":"Ringden O, Remberger M, Lehmann S et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation Bone Marrow Transplant 2000 25: 993 996","journal-title":"Bone Marrow Transplant"},{"key":"BF1703615_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-2797(97)00038-0","volume":"105","author":"GJ Mulder","year":"1997","unstructured":"Mulder GJ, Ouwerkerk-Mahadevan S . Modulation of glutathione conjugation in vivo: how to decrease glutathione conjugation in vivo or in intact cellular systems in vitro Chem Biol Interact 1997 105: 17 34","journal-title":"Chem Biol Interact"},{"key":"BF1703615_CR28","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1016\/S0021-9258(18)35980-5","volume":"254","author":"OW Griffith","year":"1979","unstructured":"Griffith OW, Meister A . Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine) J Biol Chem 1979 254: 7558 7560","journal-title":"J Biol Chem"},{"key":"BF1703615_CR29","first-page":"85","volume":"16","author":"DH Marchand","year":"1988","unstructured":"Marchand DH, Remmel RP, Abdel-Monem MM . Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat Drug Metab Dispos 1988 16: 85 92","journal-title":"Drug Metab Dispos"},{"key":"BF1703615_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF03189864","volume":"12","author":"M Hassan","year":"1987","unstructured":"Hassan M, Ehrsson H . Metabolism of 14C-busulfan in isolated perfused rat liver Eur J Drug Metab Pharmacokinet 1987 12: 71 76","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"BF1703615_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0378-4347(99)00170-X","volume":"730","author":"CA Ritter","year":"1999","unstructured":"Ritter CA, Bohnenstengel F, Hofmann U et al. Determination of tetrahydrothiophene formation as a probe of in vitro busulfan metabolism by human glutathione S-transferase A1\u20131: use of a highly sensitive gas chromatographic-mass spectrometric method J Chromatogr B Biomed Sci Appl 1999 730: 25 31","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"BF1703615_CR32","first-page":"1015","volume":"24","author":"M Czerwinski","year":"1996","unstructured":"Czerwinski M, Gibbs JP, Slattery JT . Busulfan conjugation by glutathione S-transferases alpha, mu, and pi Drug Metab Dispos 1996 24: 1015 1019","journal-title":"Drug Metab Dispos"},{"key":"BF1703615_CR33","first-page":"3678","volume":"56","author":"JP Gibbs","year":"1996","unstructured":"Gibbs JP, Czerwinski M, Slattery JT . Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases Cancer Res 1996 56: 3678 3681","journal-title":"Cancer Res"},{"key":"BF1703615_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000028359","volume":"60","author":"LD DeLeve","year":"2000","unstructured":"DeLeve LD, Wang X . Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes Pharmacology 2000 60: 143 154","journal-title":"Pharmacology"},{"key":"BF1703615_CR35","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/sj.gt.3300381","volume":"4","author":"M Czerwinski","year":"1997","unstructured":"Czerwinski M, Kiem HP, Slattery JT . Human CD34+ cells do not express glutathione S-transferases alpha Gene Ther 1997 4: 268 270","journal-title":"Gene Ther"},{"key":"BF1703615_CR36","first-page":"573","volume":"85","author":"L Wang","year":"2000","unstructured":"Wang L, Groves MJ, Hepburn MD et al. Glutathione S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymphoid lineages Haematologica 2000 85: 573 579","journal-title":"Haematologica"},{"key":"BF1703615_CR37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s002800050847","volume":"42","author":"M Hassan","year":"1998","unstructured":"Hassan M, Hassan Z, Nilsson C et al. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration Cancer Chemother Pharmacol 1998 42: 471 478","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703615_CR38","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/0003-2697(69)90064-5","volume":"27","author":"F Tietze","year":"1969","unstructured":"Tietze F . Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues Anal Biochem 1969 27: 502 522","journal-title":"Anal Biochem"},{"key":"BF1703615_CR39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL et al. Protein measurement with the folin phenol reagent J Biol Chem 1951 193: 265 275","journal-title":"J Biol Chem"},{"key":"BF1703615_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.bmt.1700891","volume":"20","author":"DS Chattergoon","year":"1997","unstructured":"Chattergoon DS, Saunders EF, Klein J et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children Bone Marrow Transplant 1997 20: 347 354","journal-title":"Bone Marrow Transplant"},{"key":"BF1703615_CR41","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood.V84.7.2357.2357","volume":"84","author":"PJ Shaw","year":"1994","unstructured":"Shaw PJ, Scharping CE, Brian RJ et al. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia Blood 1994 84: 2357 2362","journal-title":"Blood"},{"key":"BF1703615_CR42","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/jnci\/66.6.1053","volume":"66","author":"TE Spiro","year":"1981","unstructured":"Spiro TE, Mattelaer MA, Efira A et al. Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents J Natl Cancer Inst 1981 66: 1053 1059","journal-title":"J Natl Cancer Inst"},{"key":"BF1703615_CR43","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000207411","volume":"63","author":"GR Standen","year":"1980","unstructured":"Standen GR, Blackett NM . Effect of daily administration of cytotoxic drugs on the erythroid and granulocytic repopulating ability of rat bone marrow Acta Haematol 1980 63: 252 256","journal-title":"Acta Haematol"},{"key":"BF1703615_CR44","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","volume":"25","author":"M Hassan","year":"2000","unstructured":"Hassan M, Ljungman P, Ringden O et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity Bone Marrow Transplant 2000 25: 915 924","journal-title":"Bone Marrow Transplant"},{"key":"BF1703615_CR45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/BF01208843","volume":"119","author":"C Selig","year":"1993","unstructured":"Selig C, Nothdurft W, Fliedner TM . Radioprotective effect of N-acetylcysteine on granulocyte\/macrophage colony-forming cells of human bone marrow J Cancer Res Clin Oncol 1993 119: 346 349","journal-title":"J Cancer Res Clin Oncol"},{"key":"BF1703615_CR46","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/0024-3205(86)90131-1","volume":"38","author":"R Lerza","year":"1986","unstructured":"Lerza R, Bogliolo G, Muzzulini C et al. Failure of N-acetylcysteine to protect against cis-dichlorodiammineplatinum(II)-induced hematopoietic toxicity in mice Life Sci 1986 38: 1795 1800","journal-title":"Life Sci"},{"key":"BF1703615_CR47","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/0024-3205(85)90230-9","volume":"36","author":"G Massa","year":"1985","unstructured":"Massa G, Muzzulini C, Bogliolo G et al. The effect of N-acetylcysteine on toxicity of cyclophosphamide and doxorubicin on murine hemopoietic progenitors Life Sci 1985 36: 1141 1147","journal-title":"Life Sci"},{"key":"BF1703615_CR48","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s002800050678","volume":"40","author":"CB Hare","year":"1997","unstructured":"Hare CB, Elion GB, Colvin OM et al. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft Cancer Chemother Pharmacol 1997 40: 409 414","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703615","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703615.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703615.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:27:30Z","timestamp":1648078050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,1]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,8,1]]}},"alternative-id":["BF1703615"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703615","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,1]]},"assertion":[{"value":"21 January 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}